Integra LifeSciences (NSDQ:IART) said it closed its acquisition of the U.S. rights to Tornier‘s (NSDQ:TRNX) Salto Talaris and Salto Talaris XT ankle replacements and Futura silastic toe replacements.
Integra said it expects the acquisition will be immaterial to its expected adjusted earnings per share for the 1st year, and said it plans to provide info on expected revenues from the buy during an earnings call in the 3rd quarter.
“The addition of the Salto Talaris enhances our lower extremities product offering and accelerates our entry into the U.S. total ankle replacement market. We are also pleased to welcome several key employees who will be joining Integra’s commercial organization,” veep Nick Gallucci said in a press release.
Integra announced the deal last month, saying it would pick up Tornier’s assets in the U.S., as the Dutch orthopedics company looked to satisfy anti-trust regulators about its pending, $3.3 billion merger with Wright Medical (NSDQ:WMGI).
Integra did not announce the amount paid or any terms and conditions associated with the deal.
Last month, Integra hit rival HyperBranch Medical Technology with a lawsuit alleging infringement of 6 patents related to the DuraSeal neurosurgical sealant it acquired along with Confluent Surgical last year.
Covidien dealt its Confluent Surgical line to Integra in January 2014 for $235 million in up-front cash and another $30 million in milestones. Yesterday Integra said Durham, N.C.-based HyperBranch’s Adherus and Adherus Autospray dural sealants and its Adherus spinal sealant infringe 6 patents it licenses from Incept, according to court documents.
